Margaret A. Horn Sells 3,058 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) Stock

Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) COO Margaret A. Horn sold 3,058 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $119,384.32. Following the transaction, the chief operating officer now owns 153,533 shares in the company, valued at $5,993,928.32. This represents a 1.95 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Revolution Medicines Stock Down 1.0 %

RVMD traded down $0.38 during trading on Friday, reaching $38.11. 2,499,644 shares of the company's stock were exchanged, compared to its average volume of 1,347,138. Revolution Medicines, Inc. has a fifty-two week low of $29.55 and a fifty-two week high of $62.40. The company has a market capitalization of $7.09 billion, a P/E ratio of -10.62 and a beta of 1.46. The business has a 50 day moving average price of $40.55 and a 200 day moving average price of $45.73.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.11). As a group, research analysts forecast that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Remove Ads

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on RVMD. JPMorgan Chase & Co. upped their target price on Revolution Medicines from $63.00 to $71.00 and gave the stock an "overweight" rating in a research report on Tuesday, December 3rd. Needham & Company LLC decreased their price target on shares of Revolution Medicines from $60.00 to $59.00 and set a "buy" rating for the company in a report on Thursday, February 27th. Guggenheim lifted their price objective on Revolution Medicines from $82.00 to $87.00 and gave the stock a "buy" rating in a research note on Tuesday, December 3rd. Stifel Nicolaus dropped their price target on Revolution Medicines from $80.00 to $78.00 and set a "buy" rating on the stock in a research report on Thursday, February 27th. Finally, Wedbush reiterated an "outperform" rating and set a $67.00 price target on shares of Revolution Medicines in a report on Thursday, February 27th. Twelve investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Revolution Medicines currently has a consensus rating of "Buy" and an average price target of $66.31.

Hedge Funds Weigh In On Revolution Medicines

Hedge funds have recently modified their holdings of the stock. IFP Advisors Inc bought a new stake in Revolution Medicines in the fourth quarter valued at $34,000. Quarry LP acquired a new stake in shares of Revolution Medicines in the 3rd quarter valued at $82,000. Sterling Capital Management LLC increased its position in shares of Revolution Medicines by 588.7% during the 4th quarter. Sterling Capital Management LLC now owns 1,956 shares of the company's stock worth $86,000 after purchasing an additional 1,672 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in Revolution Medicines by 368.3% during the 4th quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company's stock valued at $90,000 after purchasing an additional 1,613 shares during the last quarter. Finally, Kapitalo Investimentos Ltda acquired a new position in Revolution Medicines in the fourth quarter valued at about $104,000. 94.34% of the stock is owned by institutional investors and hedge funds.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.